Condition: Prostate Cancer · Sponsor: University of California, Los Angeles
The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.
This description comes directly from the study's public registry record.
Michelle C Cardenas, MSN, NP · (310) 794-3070 · mccardenas@mednet.ucla.edu
Ankush sachdeva · 310-794-7700 · ASachdeva@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03620786